COMPANY RESEARCHHolds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
An April 2026 announcement reports first dosing in Phase 3 setidegrasib/ASP3082 for pancreatic cancer. A Japanese official registry also records first dosing in NSCLC Phase 3 in August 2026.
The flagship protein degrader is an internally developed KRAS G12D program; a separate Cullgen collaboration also exists.
The original 2025 discovery paper resolves the KRAS(G12D)/ASP3082/VHL ternary complex, supporting VHL-dependent proteasomal degradation.
An original March 2026 NEJM Phase 1 study included 203 patients and reported weekly intravenous dosing, safety, and antitumor activity. It is not used for direct cross-study ranking.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| linaclotide / LINZESS | GC-C · Constipation-related GI indications; subject to local labeling | Approved | Acts locally in the gut; systemic oral bioavailability is not the objective |
| setidegrasib / ASP3082 | KRAS G12D · Advanced solid tumors with KRAS G12D mutations | Phase 3 | Human results reported by the source; see facts and original materials for type and quality |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.